CSIMarket Company Name, Ticker, Suppliers, else..


Incyte Corporation  (NASDAQ: INCY)
Other Ticker:  
 
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare

Incyte Corporation

INCY's Fundamental analysis



Looking into Incyte growth rates, revenue grew by 23.81 % in III. Quarter 2024 from the same quarter a year ago. Ranking at No. 506

Medical Laboratories industry recorded growth of revenues by 6.58 %

Incyte's net profit decreased by -37.84 % in III. Quarter 2024 year on year, to $106 millions.

• More on INCY's Growth


Incyte
current PE on trailing twelve month basis is above Medical Laboratories industry average.

Incyte realized cash reduction of $ -9.82 per share in trailing twelve-month period.
Company
555.1
PE TTM   
Industry
-0
PE TTM    
Company's Price to Sales ratio is at 3.49.
Medical Laboratories industry's Price to Sales ratio is at 2.52.


• More on INCY's Valuation
 
 Total Debt (Millions $) -
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ 1,614,842
 Net Income/Employee (TTM) $ 12,869
 Receivable Turnover (TTM) 5.46
 Tangible Book Value (Per Share $) 14.79

Incyte
current PE on trailing twelve month basis is above Medical Laboratories industry average.

Incyte realized cash outflow of $ -9.82per share in trailing twelve-month period.
Company
555.1
PE TTM   
Industry
-0
PE TTM    
Company's Price to Sales ratio is at 3.49.
Medical Laboratories industry's Price to Sales ratio is at 2.52.

Incyte Price to Book Ratio is at 4.48 lower than Industry Avg. of 29.56. and higher than S&P 500 Avg. of 0.01

• More on INCY's Valuation

•  Market Capitalization (Millions $) 14,216
•  Shares Outstanding (Millions) 196
•  Employees 2,524
•  Revenues (TTM) (Millions $) 4,076
•  Net Income (TTM) (Millions $) 32
•  Cash Flow (TTM) (Millions $) -1,923
•  Capital Exp. (TTM) (Millions $) -85
•  Total Debt (Millions $) -
•  Dividend TTM ($) 0 $
•  Dividend Yield TTM (%) -
•  Revenue/Employee (TTM) $ 1,614,842
•  Net Income/Employee(TTM) $ 12,869
•  Receivable Turnover Ratio (TTM) 5.46
•  Tangible Book Value (Per Share $) 14.79

•  Market Capitalization (Millions $) 14,216
•  Shares Outstanding (Millions) 196
•  Employees 2,524
•  Revenues (TTM) (Millions $) 4,076
•  Net Income (TTM) (Millions $) 32
•  Cash Flow (TTM) (Millions $) -1,923
•  Capital Exp. (TTM) (Millions $) -85


    INCY's Profitability Comparisons
Incyte achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in III. Quarter 2024 to 12.84 %.

Incyte net profit margin of 9.36 % is currently ranking no. 7 in Medical Laboratories industry, ranking no. 121 in Healthcare sector and number 1373 in S&P 500.


Profitability by Segment
Total 9.36 %



  Ratio
•   Capital Ratio (MRQ) 1.87
•  Total Debt to Equity (MRQ) -
•  Tangible Leverage Ratio (MRQ) 0.64
•  Asset Turnover Ratio (TTM) 0.69
•  Inventory Turnover Ratio (TTM) 3.94



Incyte achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in III. Quarter 2024 to 12.84 %.

Incyte net profit margin of 9.36 % is currently ranking no. 7 in Medical Laboratories industry, ranking no. 121 in Healthcare sector and number 1373 in S&P 500.

• More on INCY's Key Ratios





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com